Urate, commonly known as uric acid, is a byproduct of purine metabolism that circulates through the bloodstream as it moves from cells to the kidneys for excretion. When you eat foods rich in purines—red meat, organ meats, shellfish, and certain alcoholic beverages—your body breaks down these compounds into nucleotides, which are then further metabolized into uric acid. In a healthy person, the kidneys filter approximately 1,000 milligrams of urate daily, excreting roughly 80% through urine while the digestive tract handles the remainder. Despite its reputation as a waste product, urate serves an important biochemical function as one of the body’s most powerful antioxidants, scavenging free radicals that would otherwise damage cells and contribute to aging and disease.
The journey of urate through your body reveals a carefully balanced system that usually works without notice. When this system functions properly, urate levels remain between 3.5 and 7.2 mg/dL in men and 2.6 to 6.0 mg/dL in women. However, when the kidneys cannot excrete urate efficiently, or when the body produces too much of it, levels rise—a condition called hyperuricemia. This seemingly minor metabolic disturbance can trigger cascade effects throughout the body, affecting joint health, kidney function, and even cardiovascular risk, making it relevant to anyone monitoring long-term health outcomes and healthcare costs.
Table of Contents
- HOW URATE FORMS FROM PURINES IN THE BODY
- THE KIDNEY’S ROLE IN URATE EXCRETION AND DYSFUNCTION
- HYPERURICEMIA AND THE URATE CRYSTAL CASCADE
- URATE AS A POWERFUL ANTIOXIDANT AND METABOLIC PARADOX
- MEDICATIONS AND CONDITIONS THAT DISRUPT URATE BALANCE
- GENETIC VARIATION IN URATE TRANSPORTERS
- DIETARY AND LIFESTYLE FACTORS IN URATE MANAGEMENT
- Frequently Asked Questions
HOW URATE FORMS FROM PURINES IN THE BODY
The biochemical pathway from food to urate begins with purine intake. Purines are nitrogen-containing compounds found in cell nuclei, and they arrive in your body through dietary sources and from the breakdown of your own cells during normal turnover. In the liver, the enzyme xanthine oxidase catalyzes the conversion of hypoxanthine to xanthine, and then xanthine to uric acid—the final, insoluble end product of purine metabolism in humans. This is where humans differ significantly from most other mammals: dogs and many other animals possess the enzyme uricase, which breaks uric acid down further into allantoin, a compound that is easier to excrete. Humans lost this enzyme during evolution, which means we accumulate urate at higher concentrations than other species. A single serving of beef liver (85 grams) contains roughly 150 mg of purines, while an equivalent serving of salmon contains about 70 mg.
The body also generates urate endogenously—every day, roughly 600-800 mg of urate is produced from the breakdown of your own nucleic acids as cells die and are replaced. Once urate is produced, it enters the bloodstream and circulates throughout the body in a dissolved state. In normal physiology, serum urate concentrations hover just below the saturation point where it would crystallize. This precarious balance is maintained by continuous renal clearance, as the kidneys filter urate from the blood, reabsorb much of it in the proximal tubules, and excrete the remainder. The process is complex: approximately 90% of filtered urate is reabsorbed, and some is even secreted back into the tubular fluid, meaning net urinary urate excretion depends on a fine interplay between filtration, reabsorption, and secretion. If any of these processes are disrupted—by genetic variation, dehydration, or certain medications—urate can accumulate rapidly.
THE KIDNEY’S ROLE IN URATE EXCRETION AND DYSFUNCTION
The kidneys are the primary regulators of serum urate concentration, and they operate through a multi-step process that involves specific transporters and channels. The URAT1 transporter, encoded by the SLC22A12 gene, reabsorbs the majority of filtered urate back into the bloodstream, while the GLUT9 transporter handles additional reabsorption. A separate set of transporters, particularly ABCG2, actively secretes urate into the tubular fluid for excretion. This system is exquisitely sensitive, and even small changes in expression or function of these transporters can shift the balance between retention and excretion. In a person with normal kidney function, about 8–12 mg/dL of urate circulates in the blood, but patients with chronic kidney disease often see higher levels because the progressive loss of nephrons reduces the number of filtering units available.
A patient with Stage 3 chronic kidney disease might accumulate serum urate above 8 mg/dL despite unchanged dietary intake and purine production, simply because fewer nephrons are available to clear it. Dehydration, a common but often overlooked factor, amplifies the kidney’s reabsorption of urate. During periods of reduced water intake or high fluid loss, the kidneys increase reabsorption of both water and urate to preserve blood volume. This is why acute gout attacks sometimes occur during or shortly after dehydration, fever, or strenuous exercise—all conditions that reduce urine flow. Interestingly, moderate alcohol intake does not significantly raise urate, but acute consumption of large quantities does, because ethanol inhibits urate excretion in the kidneys and simultaneously increases urate production by accelerating purine breakdown. A limitation of current understanding is that we cannot yet predict which individuals will develop hyperuricemia based solely on dietary or genetic factors; two people consuming identical diets may have serum urate levels that differ by 2–3 mg/dL due to variations in transporter expression, kidney function, and unknown metabolic factors.
HYPERURICEMIA AND THE URATE CRYSTAL CASCADE
When serum urate concentration exceeds 6.8 mg/dL—the saturation point at which urate can no longer remain dissolved at physiological pH and temperature—the stage is set for crystallization. These needle-shaped monosodium urate crystals trigger a cascade of inflammatory events when they form in joints or surrounding tissues. The immune system recognizes these crystals as danger signals, activating the NLRP3 inflammasome in macrophages and neutrophils, which then release interleukin-1 beta and other pro-inflammatory cytokines. This immune activation causes the acute inflammatory response characteristic of gout: redness, swelling, warmth, and severe pain, typically striking the big toe first because it is the coolest joint in the body, making it more favorable for crystal formation. A typical acute gout attack can render a person immobile for three to seven days and can recur multiple times per year in untreated hyperuricemia.
Beyond the joints, chronic hyperuricemia is associated with kidney damage. High urate levels can promote oxidative stress within renal tissue, leading to glomerulosclerosis and progressive loss of kidney function—a condition sometimes called uric acid nephropathy. The relationship is bidirectional: hyperuricemia damages the kidneys, but damaged kidneys then cannot excrete urate efficiently, creating a worsening cycle. Studies have shown that people with serum urate above 9 mg/dL have a 40% higher risk of developing chronic kidney disease compared to those with levels below 5 mg/dL. Additionally, elevated urate is associated with increased cardiovascular risk, though whether this is causative or merely correlative remains debated. Some evidence suggests urate itself promotes endothelial dysfunction and arterial stiffness, while other data indicate that hyperuricemia is simply a marker of other metabolic problems like insulin resistance and obesity.
URATE AS A POWERFUL ANTIOXIDANT AND METABOLIC PARADOX
Despite its reputation as a waste product, urate accounts for approximately half of the antioxidant capacity of human blood plasma. Its chemical structure, containing multiple aromatic rings, makes it exceptionally effective at neutralizing reactive oxygen species such as superoxide radicals and hydroxyl radicals. In this role, urate scavenges free radicals that would otherwise damage DNA, proteins, and lipids, potentially reducing the risk of certain cancers and degenerative diseases. This antioxidant function may explain why some studies have found a protective association between urate levels and Parkinson’s disease risk; higher serum urate is correlated with lower risk, possibly because the antioxidant action slows neurodegeneration.
However, this benefit appears to have a threshold—urate’s protective antioxidant effects are strongest at modest to normal levels, while hyperuricemia eliminates any protective benefit and instead promotes the inflammatory damage described above. This creates a metabolic paradox: the same molecule that protects against oxidative stress at normal concentrations becomes a pro-inflammatory agent when it crystallizes at elevated concentrations. From an evolutionary perspective, humans may retain relatively high baseline urate levels precisely because of its antioxidant function, possibly as compensation for losing the enzyme uricase that other mammals possess. The tradeoff is that this antioxidant benefit comes with a narrow margin—just 1 mg/dL separates protective levels from pathological hyperuricemia in many individuals, and that margin narrows further in the elderly, in men, and in those with genetic predispositions to reduced urate excretion. This explains why lowering serum urate below 6 mg/dL in people with gout leads to crystal dissolution and attack prevention, yet attempting to lower it further than necessary in asymptomatic individuals with elevated urate remains controversial and may lose the antioxidant benefit without clear clinical gain.
MEDICATIONS AND CONDITIONS THAT DISRUPT URATE BALANCE
Multiple medications and medical conditions can shift serum urate levels upward, often unexpectedly. Diuretics, particularly loop and thiazide diuretics used to treat high blood pressure and heart failure, reduce urine flow and increase urate reabsorption, making them one of the most common iatrogenic causes of hyperuricemia. Low-dose aspirin (81 mg daily), commonly taken for cardiovascular protection, also increases serum urate by decreasing renal urate excretion through the same transporter mechanisms. Conversely, high-dose aspirin (above 3 grams daily) has the opposite effect and promotes urate excretion.
Chemotherapy drugs, particularly those that kill large numbers of cancer cells rapidly, can trigger acute hyperuricemia and gout as the dying cells release their nucleic acids in a surge of purine breakdown. Allopurinol and febuxostat, xanthine oxidase inhibitors, are used to prevent hyperuricemia in cancer patients receiving chemotherapy, demonstrating the clinical significance of this problem. A critical warning: when lowering serum urate pharmacologically in people with gout, the rate of decline must be gradual. Rapid urate lowering can precipitate acute gout attacks as existing crystals partially dissolve and enter the bloodstream, triggering renewed immune activation. This counterintuitive phenomenon—that treatment causes symptom worsening—has led to treatment failures and patient abandonment of urate-lowering therapy, highlighting the need for colchicine or NSAIDs as prophylaxis during the initial weeks of urate-lowering drug therapy.
GENETIC VARIATION IN URATE TRANSPORTERS
Twin studies and genome-wide association studies have identified that 60–70% of the variation in serum urate levels among individuals is heritable, driven largely by genetic variations in the SLC22A12, ABCG2, and GLUT9 genes encoding the urate transporters and channel proteins. Certain genetic variants of SLC22A12 lead to reduced expression of the URAT1 reabsorption transporter, causing lower serum urate and increased urinary excretion. People carrying these alleles rarely develop hyperuricemia even if they consume high-purine diets.
Conversely, other common variants increase URAT1 expression or reduce ABCG2 secretion, strongly predisposing carriers to hyperuricemia and gout. A person homozygous for a hyperuricemia-risk allele of ABCG2 may develop hyperuricemia while eating a moderate diet that would pose no problem for someone with the protective variant. Ethnic variation in these alleles is substantial: certain ABCG2 variants are much more common in East Asian populations, explaining the higher prevalence of gout in those regions. This genetic underpinning means that screening for serum urate in asymptomatic individuals, and pharmacological lowering in those without symptoms, remains controversial—genetic risk does not always translate to clinical symptoms, and intervention without symptoms of gout or kidney disease lacks strong evidence of benefit.
DIETARY AND LIFESTYLE FACTORS IN URATE MANAGEMENT
The relationship between dietary purine intake and serum urate is weaker than commonly assumed; studies show that purines from food account for only about 20–30% of serum urate variation, with the remainder coming from endogenous production and kidney excretion. However, certain foods show stronger associations: red meat and organ meats raise urate more than poultry or fish, and seafood—particularly shellfish and fish roes—has a notable effect. Paradoxically, plant-based purines in vegetables, legumes, and whole grains do not significantly raise serum urate despite their high purine content; in fact, these foods are associated with lower serum urate, possibly because they are rich in fiber and other compounds that enhance urate excretion.
Fructose, whether from added sugars or fruits, increases serum urate by promoting purine synthesis and reducing renal excretion, making sugar-sweetened beverages one of the few dietary factors with robust evidence linking consumption to hyperuricemia and gout attacks. Weight loss in obese individuals can lower serum urate by 10–15%, while rapid weight loss through fasting paradoxically raises it temporarily due to concentration effects and reduced urine flow. Adequate hydration and maintenance of normal urine pH also favor urate excretion; urinary alkalinization above pH 7.5 dramatically increases urate solubility, which is why alkalization is sometimes used in clinical settings to prevent urate precipitation during chemotherapy.
- —
Frequently Asked Questions
What is the difference between urate and uric acid?
Urate and uric acid refer to the same molecule; “uric acid” is the chemical term for the protonated form, while “urate” is the ionized form that predominates in blood at physiological pH. In medical literature, the terms are used interchangeably.
Why did humans lose the ability to break down urate?
During primate evolution, the gene encoding uricase (the enzyme that converts urate to allantoin) was inactivated. This mutation persisted because urate’s potent antioxidant properties may provide evolutionary advantage; the cost of occasional gout attacks appears to have been outweighed by the benefit of enhanced cellular protection against oxidative damage.
Can you have high urate levels without symptoms?
Yes. Asymptomatic hyperuricemia affects 5–10% of the population. Most people with elevated serum urate never develop gout or kidney disease, though long-term hyperuricemia can still carry cardiovascular and renal risks. Whether to treat asymptomatic hyperuricemia remains medically controversial.
Does drinking more water really help with urate?
Increasing fluid intake does modestly lower serum urate by promoting urine flow and dilution, but the effect is small—typically 0.5–1 mg/dL. It is most useful during acute gout attacks and in people taking certain medications, but it is not a substitute for pharmacological urate-lowering therapy in symptomatic hyperuricemia.
Why do gout attacks often happen after eating a large meal or drinking alcohol?
Purine-rich foods and alcohol both acutely increase serum urate, but dehydration accompanying alcohol consumption has a larger effect. Large meals can also trigger attacks by promoting transient hyperuricemia and local pH changes in joints that favor crystal formation.